Akebia Therapeutics/$AKBA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Akebia Therapeutics
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Ticker
$AKBA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
181
Website
AKBA Metrics
BasicAdvanced
$922M
-
-$0.21
0.88
-
Price and volume
Market cap
$922M
Beta
0.88
52-week high
$4.08
52-week low
$1.07
Average daily volume
3.8M
Financial strength
Current ratio
2.234
Quick ratio
1.917
Long term debt to equity
740.584
Total debt to equity
795.72
Interest coverage (TTM)
-0.68%
Profitability
EBITDA (TTM)
10.792
Gross margin (TTM)
83.23%
Net profit margin (TTM)
-24.51%
Operating margin (TTM)
-9.55%
Revenue per employee (TTM)
$1,020,000
Management effectiveness
Return on assets (TTM)
-4.26%
Return on equity (TTM)
3,385.36%
Valuation
Price to revenue (TTM)
4.149
Price to book
37.36
Price to tangible book (TTM)
-26.65
Price to free cash flow (TTM)
-22.006
Free cash flow yield (TTM)
-4.54%
Free cash flow per share (TTM)
-0.16
Growth
Revenue change (TTM)
-1.24%
Earnings per share change (TTM)
-8.25%
3-year revenue growth (CAGR)
-5.77%
3-year earnings per share growth (CAGR)
-49.41%
10-year earnings per share growth (CAGR)
-19.94%
What the Analysts think about AKBA
Analyst ratings (Buy, Hold, Sell) for Akebia Therapeutics stock.
Bulls say / Bears say
Akebia Therapeutics reported strong Q1 2025 financial results, with total net product revenues of $55.8 million, including $12.0 million from the successful U.S. launch of Vafseo® (vadadustat) for anemia in dialysis patients. (globenewswire.com)
The company achieved a net income of $6.1 million in Q1 2025, a significant turnaround from a net loss of $18.0 million in Q1 2024, indicating improved financial health. (globenewswire.com)
Akebia strengthened its financial position by completing a $50 million public offering, ending Q1 2025 with $113.4 million in cash, providing a solid foundation for future growth. (globenewswire.com)
Despite the successful launch of Vafseo®, Akebia's total revenues for the full year 2024 were $160.18 million, a 17.70% decrease compared to 2023, indicating potential challenges in sustaining revenue growth. (stockanalysis.com)
The company's operating expenses remain high, with selling, general, and administrative expenses accounting for 44.9% of revenue and research and development expenses at 17.0% in Q1 2025, which could impact profitability. (marketbeat.com)
Akebia's total debt stands at $46.5 million, with a long-term debt to total capital ratio of 65.4%, indicating significant leverage that may pose financial risks. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
AKBA Financial Performance
Revenues and expenses
AKBA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Akebia Therapeutics stock?
Akebia Therapeutics (AKBA) has a market cap of $922M as of July 30, 2025.
What is the P/E ratio for Akebia Therapeutics stock?
The price to earnings (P/E) ratio for Akebia Therapeutics (AKBA) stock is 0 as of July 30, 2025.
Does Akebia Therapeutics stock pay dividends?
No, Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders as of July 30, 2025.
When is the next Akebia Therapeutics dividend payment date?
Akebia Therapeutics (AKBA) stock does not pay dividends to its shareholders.
What is the beta indicator for Akebia Therapeutics?
Akebia Therapeutics (AKBA) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.